PNC Financial Services Group Inc. boosted its position in DexCom, Inc. (NASDAQ:DXCM) by 19.6% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 18,420 shares of the medical device company’s stock after purchasing an additional 3,020 shares during the period. PNC Financial Services Group Inc.’s holdings in DexCom were worth $1,347,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. BNP Paribas Arbitrage SA raised its stake in shares of DexCom by 238.8% during the first quarter. BNP Paribas Arbitrage SA now owns 4,476 shares of the medical device company’s stock valued at $379,000 after acquiring an additional 3,155 shares in the last quarter. UBS Asset Management Americas Inc. raised its stake in shares of DexCom by 14.1% during the first quarter. UBS Asset Management Americas Inc. now owns 248,178 shares of the medical device company’s stock valued at $21,028,000 after acquiring an additional 30,737 shares in the last quarter. Karp Capital Management Corp bought a new stake in shares of DexCom during the first quarter valued at approximately $631,000. KBC Group NV raised its stake in shares of DexCom by 35.5% during the first quarter. KBC Group NV now owns 8,308 shares of the medical device company’s stock valued at $704,000 after acquiring an additional 2,177 shares in the last quarter. Finally, Prudential Financial Inc. raised its stake in shares of DexCom by 15.6% during the first quarter. Prudential Financial Inc. now owns 117,338 shares of the medical device company’s stock valued at $9,942,000 after acquiring an additional 15,800 shares in the last quarter.

Several analysts have recently weighed in on the stock. Wedbush reaffirmed an “outperform” rating and set a $76.00 price target (down previously from $85.00) on shares of DexCom in a research note on Thursday, September 28th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $78.00 price target on shares of DexCom in a research note on Wednesday, July 12th. Northland Securities downgraded shares of DexCom from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $85.00 to $60.00 in a research note on Thursday, September 28th. Oppenheimer Holdings, Inc. set a $92.00 price target on shares of DexCom and gave the company a “buy” rating in a research note on Wednesday, August 2nd. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $62.00 price target (down previously from $90.00) on shares of DexCom in a research note on Thursday, September 28th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and fourteen have assigned a buy rating to the stock. DexCom has an average rating of “Buy” and an average price target of $72.19.

In other DexCom news, EVP Steven Robert Pacelli sold 1,450 shares of the firm’s stock in a transaction on Monday, September 25th. The shares were sold at an average price of $69.81, for a total transaction of $101,224.50. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Richard Doubleday sold 1,635 shares of the firm’s stock in a transaction on Wednesday, August 23rd. The stock was sold at an average price of $75.26, for a total transaction of $123,050.10. Following the transaction, the executive vice president now directly owns 72,395 shares in the company, valued at $5,448,447.70. The disclosure for this sale can be found here. Insiders sold a total of 32,223 shares of company stock worth $2,285,138 over the last ninety days. Insiders own 1.70% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.watchlistnews.com/pnc-financial-services-group-inc-has-1-35-million-holdings-in-dexcom-inc-dxcm/1614601.html.

Shares of DexCom, Inc. (NASDAQ:DXCM) opened at 47.74 on Friday. The stock’s 50 day moving average is $67.67 and its 200 day moving average is $72.02. DexCom, Inc. has a 1-year low of $42.62 and a 1-year high of $88.80. The firm’s market capitalization is $4.13 billion.

DexCom (NASDAQ:DXCM) last posted its earnings results on Tuesday, August 1st. The medical device company reported ($0.16) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.07. The firm had revenue of $170.60 million for the quarter, compared to the consensus estimate of $166.54 million. DexCom had a negative net margin of 10.27% and a negative return on equity of 27.90%. The company’s revenue was up 24.3% on a year-over-year basis. During the same period last year, the firm posted ($0.24) EPS. Equities analysts predict that DexCom, Inc. will post ($0.80) earnings per share for the current year.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.